<SEC-DOCUMENT>0001213900-22-004130.txt : 20220128
<SEC-HEADER>0001213900-22-004130.hdr.sgml : 20220128
<ACCEPTANCE-DATETIME>20220128073627
ACCESSION NUMBER:		0001213900-22-004130
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220128
FILED AS OF DATE:		20220128
DATE AS OF CHANGE:		20220128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		22565335

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea154573-6k_inspiratech.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Month of: January 2022 (Report No. 3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;Form
20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 28, 2022, Inspira
Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled &ldquo;Inspira Technologies Has Listed an FDA Class I 501(k)
Exempt component of the ART system&rdquo; a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form
6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">This
Report on Form 6-K is incorporated by reference into the Registrant&rsquo;s Registration Statement on Form S-8 (Registration No.&nbsp;333-259057),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; vertical-align: top; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; vertical-align: bottom; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: #CCEEFF"><A HREF="ea154573ex99-1_inspiratech.htm">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on January 28, 2022, titled &ldquo;Inspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system.&rdquo;</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: January 28, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea154573ex99-1_inspiratech.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON JANUARY 28, 2022, TITLED "INSPIRA TECHNOLOGIES HAS LISTED AN FDA CLASS I 510(K) EXEMPT COMPONENT OF THE ART SYSTEM"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 258px; height: 63px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Inspira
Technologies Has Listed an FDA Class I 510(k) Exempt<BR>
 <U>component of the ART system</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Ra&rsquo;anana,
Israel, </B></FONT><B>January 28, 2022 &ndash; <FONT STYLE="background-color: white">Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN,
IINNW) </FONT></B><FONT STYLE="background-color: white">(the &ldquo;Company&rdquo; or &ldquo;Inspira Technologies&rdquo;), a groundbreaking
respiratory support technology company, announced today that it has listed a component of its ART and ECLS systems on the U.S. Food and
Drug Administration Class I </FONT>510(k) exempt list<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The component
is intended to reduce the potential complications associated with jugular vein cannula movement, occurring during a change of a patient&rsquo;s
posture in bed and/or during transportation. The component can also be potentially utilized in the treatment of thousands of patients
being treated each year by Extracorporeal Membrane Oxygenation (ECMO). This component is expected to allow the medical staff a safer mobilization
for the awake cannulated patients within and between hospitals and medical centers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Inspira Technologies OXY B.H.N. Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Inspira Technologies
is an innovative medical device company in the respiratory care industry. Inspira is developing the ART system, a cost effective early
extracorporeal respiratory support system for deteriorating respiratory patients. The ART system is designed to utilize a hemo-protective
flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient's need for
mechanical ventilation. The Company&rsquo;s product has not yet been tested or used in humans and has not been approved by the U.S. Food
and Drug Administration (FDA) or the CE or other regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For more information,
please visit our corporate website:&nbsp;www.inspirao2.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="width: 666px; height: 87px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 258px; height: 63px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>Forward-Looking
Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">This
press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company
is using forward-looking statements when it discusses the potential benefits related to the use of the key component and that the component
is expected to allow the medical staff a safer mobilization for the awake cannulated patients within and between hospitals and medical
centers. These forward-looking statements and their implications are based on the current expectations of the management of the Company
only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s Registration Statement on Form F-1 filed with the SEC, as well as its subsequent public filings, which are available
on the SEC&rsquo;s website, www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><U>For more details:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Miri Segal, Investor Relations, MS-IR LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">+917-607-8654, msegal@ms-ir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">MRK-ARS-010</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="width: 666px; height: 87px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( 4D# 2(  A$! Q$!_\0
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M'L1]*I?V1\9-';[8'UQRGS8%X+G/U3<V?R-?2,,,5O"D,$:11( J(BX50.P
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M\:,ZOP,]UL?^/"V_ZY+_ "%?/'P6B$GQ4OV/_+.VG8?]_%']:^A['_CPMO\
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. GP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBO/-?\<:E?:P="\'P"ZNE)$UUM
MW)'VXSQQZGCMS6=2I&FKLZ\)@JN+FXT]EJV]$EW;/0Z*\P3X;>(-5'GZYXIF
M\X_\LXMS@?B2 /P%._X5$W_0RW?_ 'Z_^RK/VM5[0_%'=]0P$=)8I7\H2:^_
M0]-HKS+_ (5$W_0RW?\ WZ_^RH_X5$W_ $,MW_WZ_P#LJ/:5OY/Q0OJ67?\
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M\KW_ !A_YY:?^<7^-&_XP_\ /+3_ ,XO\:+#]C_>7WGJE%>5[_C!_P \M/\
MSB_QI=_Q@_YY:?\ G%_C2'[#^\OO/4Z*\LW_ !@_YY:?^<7^-&_XO_\ /+3_
M ,XO\:!_5_[R^\]3HKRS?\7_ /GEI_YQ?XTN_P"+_P#SRT_\XO\ &E<?U;^_
M'[SU*BO+=_Q>_P">6G_G%_C1O^+W_/+3_P XO\:+C^J_WX_>>I45Y=O^+O\
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M_FWJPHHHK4X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW+%)"WEQ1+(S#)9@3CY5 ^8 XSSQD<<T687-.BJ][=+9:?<7C*66&)I2O0D
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M\1V,9NX[??=3VG^NBB &T<Y.YB%(&#G!XZ=:E.NV"VUC/*\D8O4$D2M&Q;!
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M@T6&!UVSSF-,>7$Q7:GS*QQQGDH"<GN>E:5%.[%9&7!H-M!<M,LLS$[<*Q7
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
